Oral VV116 versus placebo in patients with mild-to-moderate COVID-19 in China: a multicentre, double-blind, phase 3, randomised controlled study
Xiaohong Fan, Xiahong Dai, Yun Ling, Lihua Wu, Lingling Tang, Chunxian Peng, Chaolin Huang, Hongyan Liu, Hongzhou Lu, Xinghua Shen, Wei Zhang, Furong Wang, Guangming Li, Ming Li, Yanming Huang, Hongying Zhang, Minghui Li, Fei Ren, Yuanyuan Li, Chenfan Liu, Zhiguo Zhou, Wei Sun, Yongxiang Yi, Daming Zhou, Hainv Gao, Qi Pan, Hongde Liu, Jiang Zhao, Zhen Ding, Yingmin Ma, Wei Li, Quanhong Wang, Xicheng Wang, Yichun Bai, Xiangao Jiang, MM Juan Ma, PhD Bingying Xie, Kui Zhang, Dr Lanjuan Li
The Lancet Infectious Diseases, doi:10.1016/s1473-3099(23)00577-7
Background Spread of SARS-CoV-2 led to a global pandemic, and there remains unmet medical needs in the treatment of Omicron infections. VV116, an oral antiviral agent that has potent activity against SARS-CoV-2, was compared with a placebo in this phase 3 study to investigate its efficacy and safety in patients with mild-to-moderate COVID-19.
Methods This multicentre, double-blind, phase 3, randomised controlled study enrolled adults in hospitals for infectious diseases and tertiary general hospitals in China. Eligible patients were randomly assigned in a 1:1 ratio using permuted block randomisation to receive oral VV116 (0•6 g every 12 h on day 1 and 0•3 g every 12 h on days 2-5) or oral placebo (on the same schedule as VV116) for 5 days. Randomisation stratification factors included SARS-CoV-2 vaccination status and the presence of high-risk factors for progression to severe COVID-19. Inclusion criteria were a positive SARS-CoV-2 test, an initial onset of COVID-19 symptoms 3 days or less before the first study dose, and a score of 2 or more for any target COVID-19-related symptoms in the 24 h before the first dose. Patients who had severe or critical COVID-19 or who had taken any antiviral drugs were excluded from the study. The primary endpoint was the time to clinical symptom resolution for 2 consecutive days. Efficacy analyses were performed on a modified intention-to-treat population, comprising all patients who received at least one dose of VV116 or placebo, tested positive for SARS-CoV-2 nucleic acid, and did not test positive for influenza virus before the first dose. Safety analyses were done on all participants who received at least one dose of VV116 or placebo. This study was registered with ClinicalTrials.gov, NCT05582629, and has been completed. Findings A total of 1369 patients were randomly assigned to treatment groups and 1347 received either VV116 (n=674) or placebo (n=673). At the interim analysis, VV116 was superior to placebo in reducing the time to sustained clinical symptom resolution among 1229 patients (hazard ratio [HR] 1•21, 95% CI 1•04-1•40; p=0•0023). At the final analysis, a substantial reduction in time to sustained clinical symptom resolution was observed for VV116 compared with placebo among 1296 patients (HR 1•17, 95% CI 1•04-1•33; p=0•0009), consistent with the interim analysis. The incidence of adverse events was similar between groups (242 [35•9%] of 674 patients vs 283 [42•1%] of 673 patients). Interpretation Among patients with mild-to-moderate COVID-19, VV116 significantly reduced the time to sustained clinical symptom resolution compared with placebo, with no observed safety concerns.
References
Bernal, Da Silva, Musungaie, Molnupiravir for oral treatment of COVID-19 in nonhospitalized patients, N Engl J Med
Cao, Gao, Bao, VV116 versus nirmatrelvir-ritonavir for oral treatment of COVID-19, N Engl J Med
Crossfield, Chaddock, Iles, Pujades-Rodriguez, Morgan, Interplay between demographic, clinical and polygenic risk factors for severe COVID-19, Int J Epidemiol
Gottlieb, Vaca, Paredes, Early remdesivir to prevent progression to severe COVID-19 in outpatients, N Engl J Med
Guan, Ni, Hu, Clinical characteristics of coronavirus disease 2019 in China, N Engl J Med
Hammond, Leister-Tebbe, Gardner, Oral nirmatrelvir for high-risk, nonhospitalized adults with COVID-19, N Engl J Med
Hoertel, Boulware, Sánchez-Rico, Burgun, Limosin, Prevalence of contraindications to nirmatrelvir-ritonavir among hospitalized patients with COVID-19 at risk for progression to severe disease, JAMA Netw Open
Huang, Wang, Li, Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China, Lancet
Ison, Portsmouth, Yoshida, Early treatment with baloxavir marboxil in high-risk adolescent and adult outpatients with uncomplicated influenza (CAPSTONE-2): a randomised, placebo-controlled, phase 3 trial, Lancet Infect Dis
Menni, Valdes, Polidori, Symptom prevalence, duration, and risk of hospital admission in individuals infected with SARS-CoV-2 during periods of omicron and delta variant dominance: a prospective observational study from the ZOE COVID Study, Lancet
Owen, Allerton, Anderson, An oral SARS-CoV-2 M pro inhibitor clinical candidate for the treatment of COVID-19, Science
Peto, Peto, Asymptotically efficient rank invariant test procedures, J R Stat Soc [Ser A
Prentice, Linear rank tests with right censored data, Biometrika
Qian, Wang, Zhang, Safety, tolerability, and pharmacokinetics of VV116, an oral nucleoside analog against SARS-CoV-2, in Chinese healthy subjects, Acta Pharmacol Sin
Sanderson, Hisner, Donovan-Banfield, Identification of a molnupiravir-associated mutational signature in SARS-CoV-2 sequencing databases, medRxiv,
doi:10.1101/2023.01.26.23284998Shen, Lin, An open, prospective cohort study of VV116 in Chinese participants infected with SARS-CoV-2 omicron variants, Emerg Microbes Infect
Us Fda, FDA approves first oral antiviral for treatment of COVID-19 in adults
Who, WHO coronavirus (COVID-19) dashboard
Xie, Yin, Zhang, Design and development of an oral remdesivir derivative VV116 against SARS-CoV-2, Cell Res
Xue, Jing, Zhang, Milne, Wang, Infectivity versus fatality of SARS-CoV-2 mutations and influenza, Int J Infect Dis
Zhang, Dong, Liu, Gao, Risk and protective factors for COVID-19 morbidity, severity, and mortality, Clin Rev Allergy Immunol
Zhou, Wang, Diao, Zhong, Characterization of in-vivo human metabolites of the oral nucleoside anti-COVID-19 drug VV116 using UHPLC-Orbitrap-MS, J Pharm Biomed Anal
Zhu, Zhang, Wang, A novel coronavirus from patients with pneumonia in China, 2019, N Engl J Med
Zou, Peng, Shu, Antiviral efficacy and safety of molnupiravir against Omicron variant infection: a randomized controlled clinical trial, Front Pharmacol
{ 'indexed': {'date-parts': [[2023, 12, 3]], 'date-time': '2023-12-03T00:16:44Z', 'timestamp': 1701562604469},
'reference-count': 22,
'publisher': 'Elsevier BV',
'license': [ { 'start': { 'date-parts': [[2023, 11, 1]],
'date-time': '2023-11-01T00:00:00Z',
'timestamp': 1698796800000},
'content-version': 'tdm',
'delay-in-days': 0,
'URL': 'https://www.elsevier.com/tdm/userlicense/1.0/'},
{ 'start': { 'date-parts': [[2023, 11, 1]],
'date-time': '2023-11-01T00:00:00Z',
'timestamp': 1698796800000},
'content-version': 'stm-asf',
'delay-in-days': 0,
'URL': 'https://doi.org/10.15223/policy-017'},
{ 'start': { 'date-parts': [[2023, 11, 1]],
'date-time': '2023-11-01T00:00:00Z',
'timestamp': 1698796800000},
'content-version': 'stm-asf',
'delay-in-days': 0,
'URL': 'https://doi.org/10.15223/policy-037'},
{ 'start': { 'date-parts': [[2023, 11, 1]],
'date-time': '2023-11-01T00:00:00Z',
'timestamp': 1698796800000},
'content-version': 'stm-asf',
'delay-in-days': 0,
'URL': 'https://doi.org/10.15223/policy-012'},
{ 'start': { 'date-parts': [[2023, 11, 1]],
'date-time': '2023-11-01T00:00:00Z',
'timestamp': 1698796800000},
'content-version': 'stm-asf',
'delay-in-days': 0,
'URL': 'https://doi.org/10.15223/policy-029'},
{ 'start': { 'date-parts': [[2023, 11, 1]],
'date-time': '2023-11-01T00:00:00Z',
'timestamp': 1698796800000},
'content-version': 'stm-asf',
'delay-in-days': 0,
'URL': 'https://doi.org/10.15223/policy-004'}],
'content-domain': { 'domain': [ 'clinicalkey.fr', 'clinicalkey.jp', 'clinicalkey.es', 'clinicalkey.com.au',
'clinicalkey.com', 'em-consulte.com', 'thelancet.com', 'elsevier.com',
'sciencedirect.com'],
'crossmark-restriction': True},
'published-print': {'date-parts': [[2023, 11]]},
'DOI': '10.1016/s1473-3099(23)00577-7',
'type': 'journal-article',
'created': { 'date-parts': [[2023, 11, 22]],
'date-time': '2023-11-22T23:40:28Z',
'timestamp': 1700696428000},
'update-policy': 'http://dx.doi.org/10.1016/elsevier_cm_policy',
'source': 'Crossref',
'is-referenced-by-count': 1,
'title': 'Oral VV116 versus placebo in patients with mild-to-moderate COVID-19 in China: a multicentre, '
'double-blind, phase 3, randomised controlled study',
'prefix': '10.1016',
'author': [ {'given': 'Xiaohong', 'family': 'Fan', 'sequence': 'first', 'affiliation': []},
{'given': 'Xiahong', 'family': 'Dai', 'sequence': 'additional', 'affiliation': []},
{'given': 'Yun', 'family': 'Ling', 'sequence': 'additional', 'affiliation': []},
{'given': 'Lihua', 'family': 'Wu', 'sequence': 'additional', 'affiliation': []},
{'given': 'Lingling', 'family': 'Tang', 'sequence': 'additional', 'affiliation': []},
{'given': 'Chunxian', 'family': 'Peng', 'sequence': 'additional', 'affiliation': []},
{'given': 'Chaolin', 'family': 'Huang', 'sequence': 'additional', 'affiliation': []},
{'given': 'Hongyan', 'family': 'Liu', 'sequence': 'additional', 'affiliation': []},
{'given': 'Hongzhou', 'family': 'Lu', 'sequence': 'additional', 'affiliation': []},
{'given': 'Xinghua', 'family': 'Shen', 'sequence': 'additional', 'affiliation': []},
{'given': 'Wei', 'family': 'Zhang', 'sequence': 'additional', 'affiliation': []},
{'given': 'Furong', 'family': 'Wang', 'sequence': 'additional', 'affiliation': []},
{'given': 'Guangming', 'family': 'Li', 'sequence': 'additional', 'affiliation': []},
{'given': 'Ming', 'family': 'Li', 'sequence': 'additional', 'affiliation': []},
{'given': 'Yanming', 'family': 'Huang', 'sequence': 'additional', 'affiliation': []},
{'given': 'Hongying', 'family': 'Zhang', 'sequence': 'additional', 'affiliation': []},
{'given': 'Minghui', 'family': 'Li', 'sequence': 'additional', 'affiliation': []},
{'given': 'Fei', 'family': 'Ren', 'sequence': 'additional', 'affiliation': []},
{'given': 'Yuanyuan', 'family': 'Li', 'sequence': 'additional', 'affiliation': []},
{'given': 'Chenfan', 'family': 'Liu', 'sequence': 'additional', 'affiliation': []},
{'given': 'Zhiguo', 'family': 'Zhou', 'sequence': 'additional', 'affiliation': []},
{'given': 'Wei', 'family': 'Sun', 'sequence': 'additional', 'affiliation': []},
{'given': 'Yongxiang', 'family': 'Yi', 'sequence': 'additional', 'affiliation': []},
{'given': 'Daming', 'family': 'Zhou', 'sequence': 'additional', 'affiliation': []},
{'given': 'Hainv', 'family': 'Gao', 'sequence': 'additional', 'affiliation': []},
{'given': 'Qi', 'family': 'Pan', 'sequence': 'additional', 'affiliation': []},
{'given': 'Hongde', 'family': 'Liu', 'sequence': 'additional', 'affiliation': []},
{'given': 'Jiang', 'family': 'Zhao', 'sequence': 'additional', 'affiliation': []},
{'given': 'Zhen', 'family': 'Ding', 'sequence': 'additional', 'affiliation': []},
{'given': 'Yingmin', 'family': 'Ma', 'sequence': 'additional', 'affiliation': []},
{'given': 'Wei', 'family': 'Li', 'sequence': 'additional', 'affiliation': []},
{'given': 'Quanhong', 'family': 'Wang', 'sequence': 'additional', 'affiliation': []},
{'given': 'Xicheng', 'family': 'Wang', 'sequence': 'additional', 'affiliation': []},
{'given': 'Yichun', 'family': 'Bai', 'sequence': 'additional', 'affiliation': []},
{'given': 'Xiangao', 'family': 'Jiang', 'sequence': 'additional', 'affiliation': []},
{'given': 'Juan', 'family': 'Ma', 'sequence': 'additional', 'affiliation': []},
{'given': 'Bingying', 'family': 'Xie', 'sequence': 'additional', 'affiliation': []},
{'given': 'Kui', 'family': 'Zhang', 'sequence': 'additional', 'affiliation': []},
{'given': 'Lanjuan', 'family': 'Li', 'sequence': 'additional', 'affiliation': []}],
'member': '78',
'reference': [ { 'key': '10.1016/S1473-3099(23)00577-7_bib3',
'doi-asserted-by': 'crossref',
'first-page': '727',
'DOI': '10.1056/NEJMoa2001017',
'article-title': 'A novel coronavirus from patients with pneumonia in China, 2019',
'volume': '382',
'author': 'Zhu',
'year': '2020',
'journal-title': 'N Engl J Med'},
{ 'key': '10.1016/S1473-3099(23)00577-7_bib4',
'doi-asserted-by': 'crossref',
'first-page': '1708',
'DOI': '10.1056/NEJMoa2002032',
'article-title': 'Clinical characteristics of coronavirus disease 2019 in China',
'volume': '382',
'author': 'Guan',
'year': '2020',
'journal-title': 'N Engl J Med'},
{ 'key': '10.1016/S1473-3099(23)00577-7_bib5',
'doi-asserted-by': 'crossref',
'first-page': '497',
'DOI': '10.1016/S0140-6736(20)30183-5',
'article-title': 'Clinical features of patients infected with 2019 novel coronavirus in '
'Wuhan, China',
'volume': '395',
'author': 'Huang',
'year': '2020',
'journal-title': 'Lancet'},
{ 'key': '10.1016/S1473-3099(23)00577-7_bib6',
'doi-asserted-by': 'crossref',
'first-page': '90',
'DOI': '10.1007/s12016-022-08921-5',
'article-title': 'Risk and protective factors for COVID-19 morbidity, severity, and '
'mortality',
'volume': '64',
'author': 'Zhang',
'year': '2023',
'journal-title': 'Clin Rev Allergy Immunol'},
{ 'key': '10.1016/S1473-3099(23)00577-7_bib7',
'doi-asserted-by': 'crossref',
'first-page': '1384',
'DOI': '10.1093/ije/dyac137',
'article-title': 'Interplay between demographic, clinical and polygenic risk factors for '
'severe COVID-19',
'volume': '51',
'author': 'Crossfield',
'year': '2022',
'journal-title': 'Int J Epidemiol'},
{ 'key': '10.1016/S1473-3099(23)00577-7_bib8',
'doi-asserted-by': 'crossref',
'first-page': '305',
'DOI': '10.1056/NEJMoa2116846',
'article-title': 'Early remdesivir to prevent progression to severe COVID-19 in '
'outpatients',
'volume': '386',
'author': 'Gottlieb',
'year': '2022',
'journal-title': 'N Engl J Med'},
{ 'key': '10.1016/S1473-3099(23)00577-7_bib11',
'article-title': 'Identification of a molnupiravir-associated mutational signature in '
'SARS-CoV-2 sequencing databases',
'author': 'Sanderson',
'year': '2023',
'journal-title': 'medRxiv'},
{ 'key': '10.1016/S1473-3099(23)00577-7_bib12',
'doi-asserted-by': 'crossref',
'first-page': '509',
'DOI': '10.1056/NEJMoa2116044',
'article-title': 'Molnupiravir for oral treatment of COVID-19 in nonhospitalized patients',
'volume': '386',
'author': 'Jayk Bernal',
'year': '2022',
'journal-title': 'N Engl J Med'},
{ 'key': '10.1016/S1473-3099(23)00577-7_bib13',
'doi-asserted-by': 'crossref',
'DOI': '10.3389/fphar.2022.939573',
'article-title': 'Antiviral efficacy and safety of molnupiravir against Omicron variant '
'infection: a randomized controlled clinical trial',
'volume': '13',
'author': 'Zou',
'year': '2022',
'journal-title': 'Front Pharmacol'},
{ 'key': '10.1016/S1473-3099(23)00577-7_bib14',
'doi-asserted-by': 'crossref',
'first-page': '1397',
'DOI': '10.1056/NEJMoa2118542',
'article-title': 'Oral nirmatrelvir for high-risk, nonhospitalized adults with COVID-19',
'volume': '386',
'author': 'Hammond',
'year': '2022',
'journal-title': 'N Engl J Med'},
{ 'key': '10.1016/S1473-3099(23)00577-7_bib15',
'doi-asserted-by': 'crossref',
'first-page': '1586',
'DOI': '10.1126/science.abl4784',
'article-title': 'An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment '
'of COVID-19',
'volume': '374',
'author': 'Owen',
'year': '2021',
'journal-title': 'Science'},
{ 'key': '10.1016/S1473-3099(23)00577-7_bib16',
'doi-asserted-by': 'crossref',
'DOI': '10.1001/jamanetworkopen.2022.42140',
'article-title': 'Prevalence of contraindications to nirmatrelvir-ritonavir among '
'hospitalized patients with COVID-19 at risk for progression to severe '
'disease',
'volume': '5',
'author': 'Hoertel',
'year': '2022',
'journal-title': 'JAMA Netw Open'},
{ 'key': '10.1016/S1473-3099(23)00577-7_bib17',
'doi-asserted-by': 'crossref',
'first-page': '1212',
'DOI': '10.1038/s41422-021-00570-1',
'article-title': 'Design and development of an oral remdesivir derivative VV116 against '
'SARS-CoV-2',
'volume': '31',
'author': 'Xie',
'year': '2021',
'journal-title': 'Cell Res'},
{ 'key': '10.1016/S1473-3099(23)00577-7_bib18',
'doi-asserted-by': 'crossref',
'DOI': '10.1016/j.jpba.2023.115340',
'article-title': 'Characterization of in-vivo human metabolites of the oral nucleoside '
'anti-COVID-19 drug VV116 using UHPLC-Orbitrap-MS',
'volume': '228',
'author': 'Zhou',
'year': '2023',
'journal-title': 'J Pharm Biomed Anal'},
{ 'key': '10.1016/S1473-3099(23)00577-7_bib19',
'doi-asserted-by': 'crossref',
'first-page': '1518',
'DOI': '10.1080/22221751.2022.2078230',
'article-title': 'An open, prospective cohort study of VV116 in Chinese participants '
'infected with SARS-CoV-2 omicron variants',
'volume': '11',
'author': 'Shen',
'year': '2022',
'journal-title': 'Emerg Microbes Infect'},
{ 'key': '10.1016/S1473-3099(23)00577-7_bib20',
'doi-asserted-by': 'crossref',
'first-page': '3130',
'DOI': '10.1038/s41401-022-00895-6',
'article-title': 'Safety, tolerability, and pharmacokinetics of VV116, an oral nucleoside '
'analog against SARS-CoV-2, in Chinese healthy subjects',
'volume': '43',
'author': 'Qian',
'year': '2022',
'journal-title': 'Acta Pharmacol Sin'},
{ 'key': '10.1016/S1473-3099(23)00577-7_bib21',
'doi-asserted-by': 'crossref',
'first-page': '406',
'DOI': '10.1056/NEJMoa2208822',
'article-title': 'VV116 versus nirmatrelvir–ritonavir for oral treatment of COVID-19',
'volume': '388',
'author': 'Cao',
'year': '2023',
'journal-title': 'N Engl J Med'},
{ 'key': '10.1016/S1473-3099(23)00577-7_bib22',
'doi-asserted-by': 'crossref',
'first-page': '1204',
'DOI': '10.1016/S1473-3099(20)30004-9',
'article-title': 'Early treatment with baloxavir marboxil in high-risk adolescent and '
'adult outpatients with uncomplicated influenza (CAPSTONE-2): a '
'randomised, placebo-controlled, phase 3 trial',
'volume': '20',
'author': 'Ison',
'year': '2020',
'journal-title': 'Lancet Infect Dis'},
{ 'key': '10.1016/S1473-3099(23)00577-7_bib23',
'doi-asserted-by': 'crossref',
'first-page': '195',
'DOI': '10.1016/j.ijid.2022.05.031',
'article-title': 'Infectivity versus fatality of SARS-CoV-2 mutations and influenza',
'volume': '121',
'author': 'Xue',
'year': '2022',
'journal-title': 'Int J Infect Dis'},
{ 'key': '10.1016/S1473-3099(23)00577-7_bib24',
'doi-asserted-by': 'crossref',
'first-page': '1618',
'DOI': '10.1016/S0140-6736(22)00327-0',
'article-title': 'Symptom prevalence, duration, and risk of hospital admission in '
'individuals infected with SARS-CoV-2 during periods of omicron and '
'delta variant dominance: a prospective observational study from the ZOE '
'COVID Study',
'volume': '399',
'author': 'Menni',
'year': '2022',
'journal-title': 'Lancet'},
{ 'key': '10.1016/S1473-3099(23)00577-7_bib25',
'doi-asserted-by': 'crossref',
'first-page': '185',
'DOI': '10.2307/2344317',
'article-title': 'Asymptotically efficient rank invariant test procedures',
'volume': '135',
'author': 'Peto',
'year': '1972',
'journal-title': 'J R Stat Soc [Ser A]'},
{ 'key': '10.1016/S1473-3099(23)00577-7_bib26',
'doi-asserted-by': 'crossref',
'first-page': '167',
'DOI': '10.1093/biomet/65.1.167',
'article-title': 'Linear rank tests with right censored data',
'volume': '65',
'author': 'Prentice',
'year': '1978',
'journal-title': 'Biometrika'}],
'container-title': 'The Lancet Infectious Diseases',
'original-title': [],
'language': 'en',
'link': [ { 'URL': 'https://api.elsevier.com/content/article/PII:S1473309923005777?httpAccept=text/xml',
'content-type': 'text/xml',
'content-version': 'vor',
'intended-application': 'text-mining'},
{ 'URL': 'https://api.elsevier.com/content/article/PII:S1473309923005777?httpAccept=text/plain',
'content-type': 'text/plain',
'content-version': 'vor',
'intended-application': 'text-mining'}],
'deposited': { 'date-parts': [[2023, 12, 2]],
'date-time': '2023-12-02T12:51:07Z',
'timestamp': 1701521467000},
'score': 1,
'resource': {'primary': {'URL': 'https://linkinghub.elsevier.com/retrieve/pii/S1473309923005777'}},
'subtitle': [],
'short-title': [],
'issued': {'date-parts': [[2023, 11]]},
'references-count': 22,
'alternative-id': ['S1473309923005777'],
'URL': 'http://dx.doi.org/10.1016/S1473-3099(23)00577-7',
'relation': {},
'ISSN': ['1473-3099'],
'subject': ['Infectious Diseases'],
'container-title-short': 'The Lancet Infectious Diseases',
'published': {'date-parts': [[2023, 11]]},
'assertion': [ {'value': 'Elsevier', 'name': 'publisher', 'label': 'This article is maintained by'},
{ 'value': 'Oral VV116 versus placebo in patients with mild-to-moderate COVID-19 in China: '
'a multicentre, double-blind, phase 3, randomised controlled study',
'name': 'articletitle',
'label': 'Article Title'},
{ 'value': 'The Lancet Infectious Diseases',
'name': 'journaltitle',
'label': 'Journal Title'},
{ 'value': 'https://doi.org/10.1016/S1473-3099(23)00577-7',
'name': 'articlelink',
'label': 'CrossRef DOI link to publisher maintained version'},
{ 'value': 'https://doi.org/10.1016/S1473-3099(23)00633-3',
'name': 'associatedlink',
'label': 'CrossRef DOI link to the associated document'},
{'value': 'article', 'name': 'content_type', 'label': 'Content Type'},
{ 'value': '© 2023 Elsevier Ltd. All rights reserved.',
'name': 'copyright',
'label': 'Copyright'}]}
